Tribute Pharmaceuticals Trading on TSX Venture Exchange
May 27 2014 - 7:30AM
Marketwired
Tribute Pharmaceuticals Trading on TSX Venture Exchange
MILTON, ONTARIO--(Marketwired - May 27, 2014) - Tribute
Pharmaceuticals Canada Inc. (TSX-VENTURE:TRX)(OTCQB:TBUFF)
("Tribute" or the "Company"), a specialty pharmaceutical company
with a primary focus on the acquisition, licensing, development and
promotion of healthcare products in Canada and the U.S., announced
that effective with the opening of the market today, the Company's
common stock is trading under the symbol "TRX" on the TSX Venture
Exchange ("TSX-V").
Rob Harris,
President and CEO for Tribute commented, "This is a very
significant event for us today, being Tribute's first day trading
on the TSX-V. As a Canadian specialty pharmaceutical company,
primarily focused on the Canadian marketplace with offices in both
Milton, Ontario and London, Ontario, the TSX.-V listing provides
Tribute with greater access to the Canadian capital markets and
Canadian investors."
About Tribute Pharmaceuticals Canada
Inc.
Tribute is a
specialty pharmaceutical company with a primary focus on the
acquisition, licensing, development and promotion of healthcare
products in Canada and the U.S. markets.
Tribute markets
Cambia® (diclofenac potassium for oral solution), Bezalip® SR
(bezafibrate), Soriatane® (acitretin), NeoVisc® (1.0% sodium
hyaluronate solution) Uracyst® (sodium chondroitin sulfate solution
2%) and Collatamp G® in the Canadian market. Additionally, NeoVisc®
and Uracyst® are commercially available and are sold globally
through various international partnerships. Tribute also has the
exclusive U.S. rights to develop and commercialize Bezalip® SR in
the U.S. and has the exclusive right to sell bilastine a product
licensed from Faes Farma for the treatment of Allergic Rhinitis and
Chronic Idiopathic Urticaria (hives) in Canada. The exclusive
license is inclusive of prescription and non-prescription rights
for bilastine, as well as adult and pediatric presentations in
Canada. This product is subject to receiving Canadian regulatory
approval.
Tribute Pharmaceuticals'
Forward-Looking Statement
This press release
contains certain forward-looking statements about Tribute as
defined in the Private Securities Litigation Reform Act of 1995,
which statements can be identified by the use of forward-looking
terminology, such as "may", "will", "expect", "intend",
"anticipate", "estimate", "predict", "plan" or "continue" or the
negative thereof or other variations thereon or comparable
terminology referring to future events or results. Forward-looking
statements, by their nature, are subject to risks and
uncertainties, Tribute actual results could differ materially from
those anticipated in these forward-looking statements as a result
of numerous factors, any of which could cause actual results to
vary materially from current results or anticipated future results.
See Tribute reports filed with the Canadian Securities Regulatory
Authorities and the U.S. Securities and Exchange Commission from
time to time for cautionary statements identifying important
factors with respect to such forward-looking statements, including
certain risks and uncertainties that could cause actual results to
differ materially from results referred to in forward-looking
statements. Tribute assumes no obligation to update the information
contained in this press release to update forward-looking
statements to reflect changed assumptions, the occurrence of
anticipated events or changes in future operating results,
financial condition or business over time.
Bezalip® SR and
Soriatane® are registered trademarks and under license from Actavis
Group PTC ehf. Cambia® is a registered trademark and under license
from Depomed, Inc. Collatamp G® is a registered trademark and under
license EUSA Pharma (Europe) Limited.
For further
information on Tribute visit the Company's website:
http://www.tributepharma.com
Neither TSX
Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this
release.
Tribute Pharmaceuticals Canada Inc.Scott
LangilleCFO905-876-3166scott.langille@tributepharma.comwww.tributepharma.comKevin
FicklePresident, Nuwa Group LLC(925)
330-8315Kevin@nuwagroup.com
Tribute Pharmaceuticals Canada (TSXV:TRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tribute Pharmaceuticals Canada (TSXV:TRX)
Historical Stock Chart
From Jul 2023 to Jul 2024